The document discusses pharmaceutical pricing for Canadians and innovative approaches to ensuring access to innovative medicines. It notes that the Canadian reimbursement environment is evolving, with various organizations assessing price and value to find the balance between innovation and patient access. The presentation argues that medicines must be priced to both ensure patient access today and incentivize investment in biomedical research to develop treatments for patients tomorrow.

1. What price is right?
Pharmaceutical pricing
for Canadians.
Carole Watson, Director, Strategic Pricing, Janssen Inc.
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver

2. GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver
Artwork by Sebastian Ferreira
Janssen is proud to feature artwork created by people affected
by the illnesses and diseases we are committed to treating and preventing.

3. GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver
.
Then Now
Types of medicines: Large populations + lower cost / patient Small populations + higher cost / patient
Local pricing decisions Globalized pricing frameworks
List Prices HTA, ICERs
pCPA: Confidential rebates
Private Payer agreements
Wide array of science Targeted science
Innovation threshold lower Higher innovation level required for success
R&D investment – large scale centres R&D investment across the Life Sciences Ecosystem
Randomized Controlled Trials RCTs + Real World Evidence
Stronger economies Prolonged economic slowdown
Younger populations Older populations
Treated in hospitals Treated in the community

4. Canadian reimbursement environment is still
rapidly evolving
Health Canada
Patented Medicine Prices
Review Board
HTA (CDR, INESSS,
pCODR)
Pan Canadian Pharmaceutical
Alliance (pCPA)
Private Insurer
Assessments
Provincial Payer Listings
(PLAs)
“Drugwatch” type
programs
Price and value
hurdles between
innovation and
patients in Canada
3/29/17
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver

5. 3/29/17
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver

6. § Patients are always at the center
§ Broad understanding of value –
to patients, healthcare system, society
§ Access for patients today
§ Incentive for investment in
biomedical innovation to transform the
lives of patients tomorrow
Medicines are priced to ensure patient access
today – and tomorrow
3/29/17
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver
.

7. Source: CIHI (NHEX), PMPRB Annual Report 2015, Statistics Canada. Methodology inspired by Brett Skinner. Spending on Patented Medicines in Canada. CHPI, 2016. Calculations by Innovative Medicines
Canada, September 2016..
*CAGR 2005-2014
15
%
25
%
60
%
0
1000
2000
3000
4000
5000
6000
+4.1% CAGR*
Non-Drug Costs: +8.4% CAGR*
Patented Drugs: +0.8% CAGR*
Healthcare Sustainability: Innovative Drugs and Beyond
$, Per Capita
20%
32%
48%
Non-drug
costs
Non-Patented
drugs
Patented
drugs
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver
.
Non-Patented Drugs: +7.6% CAGR*
Total Drug Costs:
All Other Health,
Excluding Drugs

8. Dr. Paul Janssen
“There are still many diseases
for which there is no cure, and
effective medicines must be
found.
Although we have contributed to
the solutions for some of these
problems, we will continue our
research efforts, because so
much more needs to be done.”
3/29/17
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver
.

9. What price is right?
Pharmaceutical pricing
for Canadians.
Carole Watson, Director, Strategic Pricing, Janssen Inc.
GETTING TO ACCESS
Innovative approaches to innovative medicines
Canadian Organization for Rare Disorders
March 29, 2017. Vancouver